Published on
Pathology- Multiple Sclerosis (MS)
This guide summarizes key information on Multiple Sclerosis to aid understanding and effective study.
I. Definition & Epidemiology:
  • Definition: MS is a relapsing-remitting, demyelinating disease of the Central Nervous System (CNS). Neurological disturbances affect different CNS areas at different times. Think intermittent attacks in different locations.
  • Epidemiology:
    • Peak onset: 20-30 years old.
    • Slightly more common in females.
    • Significant geographical variation: higher incidence at higher latitudes (farther from the equator), near absence near the equator. This hints at environmental factors.
II. Aetiology & Pathogenesis:
  • Aetiology (Cause): Unknown. Leading hypothesis: immune-mediated demyelination triggered by a childhood infection in genetically susceptible individuals. Think infection + genetics = trigger.
  • Pathogenesis (Mechanism):
    • Demyelination episodes cause acute neurological deficits (symptoms) developing over days and lasting weeks.
    • Early stages: Complete recovery is typical.
    • Progression: Slower recovery, residual deficits, axonal death, and permanent disability due to extensive axonal loss. Think initial recovery, then progressive damage.
III. Clinical Presentation: (Note the association between location of demyelination and symptoms)
  • Optic Nerve: Blurred vision, loss of color vision.
  • Cerebellum: Vertigo, incoordination.
  • Brainstem: Eye movement disorders.
  • Spinal Cord: Patchy numbness/tingling, progressing to paraplegia (paralysis of lower limbs), incontinence, and sexual dysfunction.
IV. Macroscopic & Microscopic Findings:
  • Macroscopy (Gross Examination): Well-circumscribed grey plaques in CNS white matter. Common locations: optic nerves, periventricular white matter, brainstem, cervical spinal cord. Think visible lesions in specific areas.
  • Histopathology (Microscopic Examination):
    • Active plaques: Inflammatory infiltrate, myelin sheath destruction.
    • Established plaques: Complete myelin loss, reduced oligodendrocytes (myelin-producing cells), relatively normal or slightly reduced axon numbers (initially).
V. Prognosis:
  • Most patients experience progressive disease.
  • Significant complications due to disability: pneumonia, urinary tract infections, pressure sores. Think disability leads to secondary complications.
Key Concepts to Remember:
  • Relapsing-remitting: Periods of attacks followed by periods of remission (partial or complete recovery).
  • Demyelination: Damage to the myelin sheath surrounding nerve fibers, impairing signal transmission.
  • Geographical variation: Strong evidence for environmental influence.
  • Progressive axonal loss: The ultimate cause of permanent disability.
  • Location-specific symptoms: The location of the demyelination dictates the presenting symptoms.
Picture
Published on
Pathology- Cerebral Infections
I. Encephalitis
A. Definition: Infection of the brain parenchyma (functional tissue of the brain).
B. Etiology: Primarily viral, most commonly Herpes Simplex Virus (HSV).
C. Pathogenesis: HSV encephalitis typically results from reactivation of latent HSV in the trigeminal ganglion, leading to infection of the temporal lobe.
D. Presentation: * Confusion * Behavioral changes * Altered consciousness * Seizures (severe cases) * Key diagnostic clue: Simultaneous perioral (around the mouth) involvement.
E. Diagnosis: * Imaging: Brain imaging (e.g., MRI) may show temporal lobe abnormalities. * Laboratory: Polymerase chain reaction (PCR) on cerebrospinal fluid (CSF) to identify HSV DNA. * Histology: Necrotizing inflammation with characteristic herpetic intranuclear inclusions in neurons and glial cells (post-mortem).
F. Treatment: Urgent antiviral treatment is essential.

II. Cerebral Abscess
A. Definition: Localized brain infection with tissue destruction.
B. Etiology: Primarily bacterial, often mixed infections.
C. Pathogenesis: * Direct spread: From paranasal sinuses, middle ear, or teeth. * Hematogenous spread: From septic emboli (e.g., infective endocarditis).
D. Presentation: Symptoms of an infected intracranial mass: * Headache * Nausea * Vomiting * Fever * Seizures * Focal neurological signs (depending on abscess location).
E. Diagnosis: Primarily through CT scan.
F. Treatment: Surgical drainage and prolonged antibiotic therapy.
G. Prognosis: High mortality (20%) and significant morbidity (50% of survivors have persistent neurological deficits or epilepsy).

III. Progressive Multifocal Leukoencephalopathy (PML)
A. Definition: Demyelinating disease of the central nervous system white matter.
B. Etiology: JC virus (polyomavirus).
C. Risk Factors: Virtually exclusive to immunocompromised individuals (e.g., HIV/AIDS, transplant recipients).
D. Pathogenesis: JC virus infection leads to multiple foci of demyelination in the white matter, which can coalesce.
E. Histology: Viral inclusions in the nuclei of astrocytes, macrophages, and oligodendrocytes within demyelinated areas.
F. Diagnosis: * Clinical presentation: Neurological symptoms. * Imaging: Characteristic MRI findings. * Laboratory: Detection of JC virus DNA in CSF.
G. Prognosis: High mortality (up to 50% within 3 months).


Picture
Published on
Pathology-Meningitis
I. Definition:
  • Infection of the subarachnoid space (the area between the brain and the protective membranes).
II. Epidemiology (Incidence Rates):
  • Viral Meningitis: Approximately 11 cases per 100,000 people per year.
  • Bacterial Meningitis: Approximately 3 cases per 100,000 people per year. Note the significantly lower incidence compared to viral meningitis.
III. Microbiology (Causative Agents):
  • Viral Meningitis: Most commonly caused by echoviruses and coxsackieviruses. No organism is cultured from CSF.
  • Bacterial Meningitis:
    • Most common causes: Neisseria meningitidis (meningococcus) and Streptococcus pneumoniae (pneumococcus).
    • Neonates (newborns): Escherichia coli and Group B streptococci are significant causes.
    • CSF culture and/or blood cultures will yield the causative organism.
IV. Pathogenesis (Disease Development):
  • Bacterial Meningitis: Bacteria typically enter the bloodstream from the nasal cavity (often following a viral upper respiratory infection). Their capsules provide resistance to phagocytosis (immune cell engulfment) and complement (part of the immune system). Bacteria exploit weaknesses in the blood-brain barrier (e.g., the choroid plexus) to access the subarachnoid space. Rapid bacterial multiplication in the cerebrospinal fluid (CSF) triggers an acute inflammatory response within the meninges.
  • Viral Meningitis: The pathogenic mechanisms are less detailed in the provided text, but it implies a similar entry point via the bloodstream but without the bacterial capsule-related resistance to immune response.
V. Presentation (Symptoms):
  • Common Symptoms (both viral and bacterial): Headache, fever, neck stiffness (meningismus), photophobia (light sensitivity).
  • Severity: Bacterial meningitis typically presents with more severe symptoms than viral meningitis.
VI. Diagnosis:
  • Lumbar Puncture (Spinal Tap): CSF analysis is crucial.
    • Viral Meningitis: CSF will show a predominance of lymphocytes (a type of white blood cell).
    • Bacterial Meningitis: CSF will show a predominance of neutrophils (another type of white blood cell).
  • Gram Staining (Bacterial Meningitis): Helps identify the bacteria present in the CSF, aiding in rapid diagnosis and treatment.
  • Culture (Bacterial Meningitis): CSF and/or blood cultures are used to grow and identify the specific bacteria.
VII. Prognosis (Outcome):
  • Viral Meningitis: Generally mild, with complete recovery expected.
  • Bacterial Meningitis: Much more serious; potentially life-threatening if not treated promptly with appropriate antibiotics. Severe cases can lead to permanent neurological complications including hearing loss, learning disabilities, paralysis, and epilepsy.​
Picture
Published on
Pathology - Subarachnoid Hemorrhage (SAH)
I. Definition & Epidemiology:
  • Definition: Bleeding into the subarachnoid space (the space between the arachnoid mater and pia mater surrounding the brain).
  • Incidence: Approximately 8 cases per 100,000 people annually.
  • Age of Onset: Most common in adults aged 35-65.
II. Etiology & Pathogenesis:
  • Primary Cause: Rupture of a berry aneurysm (a small, saccular aneurysm, usually at arterial bifurcations).
  • Aneurysm Formation: Hypothesized to result from a congenital defect in the tunica media (middle layer) of cerebral vessels, exacerbated by later-life atherosclerosis and hypertension. Crucially, most berry aneurysms do not rupture.
  • Location of Aneurysms: Most commonly found at the base of the brain, specifically:
    • Anterior communicating artery (40%)
    • Middle cerebral artery (34%)
    • Internal carotid artery (20%)
    • Posterior cerebral artery (4%)
  • Rupture Mechanism: Rupture leads to extensive subarachnoid hemorrhage, potentially extending into the brain parenchyma (brain tissue itself).
III. Clinical Presentation:
  • Cardinal Symptom: Sudden, severe headache, often described as a "thunderclap" headache or feeling like being hit on the back of the head.
  • Precipitating Factors: Exertion or straining can trigger rupture.
  • Severity: Can range from unconsciousness to immediate death in severe cases.
IV. Macroscopic & Microscopic Findings:
  • Macroscopy: Blood is found in the subarachnoid space, frequently accumulating around the circle of Willis at the brain's base. The ruptured berry aneurysm may be visible after clot removal.
  • Histopathology: The aneurysm wall lacks a muscular media layer; it consists of a thick fibrous intima (inner layer) and an outer adventitia (outer layer).
V. Prognosis:
  • Tripartite Outcome: Prognosis is generally categorized into thirds:
    • ⅓ Immediate Death: Due to tonsillar herniation (brain stem compression) from massive intracranial pressure increase.
    • ⅓ Unconscious with High Risk: High risk of mortality or permanent neurological deficits.
    • ⅓ Good Outcome: Provided there is no re-bleeding.
VI. Key Concepts for Understanding:
  • Congenital Weakness: The underlying congenital defect in the arterial wall is crucial to understanding aneurysm formation.
  • Atherosclerosis & Hypertension: These conditions exacerbate the congenital weakness, increasing rupture risk.
  • Location Matters: The specific location of aneurysms dictates potential neurological consequences based on affected arteries.
  • Rapid Onset: The sudden, severe headache is a hallmark symptom reflecting the acute nature of the hemorrhage.
  • Variable Outcome: The significant variability in outcomes highlights the severity and unpredictable nature of SAH.​
Picture
Published on
Pathology - Intracerebral Haemorrhage (ICH)
I. Definition:
  • Spontaneous (non-traumatic) bleeding into the brain tissue. Crucially, this differentiates it from other types of strokes.
II. Epidemiology:
  • Accounts for approximately 20% of all strokes.
  • Predominantly affects individuals in late middle age. Note the age range for highest risk.
III. Aetiology (Causes):
  • Hypertension (High Blood Pressure): This is the most frequent cause. Understand the strong link between uncontrolled hypertension and ICH.
  • Less Common Causes: These are important to remember for differential diagnosis:
    • Cerebral amyloid angiopathy (CAA)
    • Ruptured arteriovenous malformation (AVM)
    • Coagulation disorders (problems with blood clotting)
IV. Pathogenesis (Mechanism):
  • Hypertension-related ICH: Mostly caused by the rupture of Charcot-Bouchard microaneurysms (small, weakened areas in blood vessels). Focus on understanding this key mechanism.
  • Haematoma Formation: The resulting blood clot (hematoma) destroys brain tissue and rapidly increases intracranial pressure (ICP). This pressure increase is the primary cause of morbidity and mortality.
V. Clinical Presentation:
  • Sudden Onset: The symptoms appear abruptly.
  • Focal Neurological Deficits: Symptoms depend on the location of the bleed. Remember that the location dictates the specific neurological symptoms.
  • Raised Intracranial Pressure (ICP) Symptoms: These are common and can include headache, vomiting, altered consciousness.
  • Mortality Risk:
    • Large hemorrhages can cause death rapidly due to high ICP and herniation (brain tissue displacement).
    • Even small hemorrhages in vital brainstem areas (controlling breathing and heart rate) can be fatal.
VI. Macroscopic Findings (Gross Examination):
  • Haematoma: Visible blood clot replacing brain tissue.
  • Mass Effect: The hematoma pushes on surrounding brain structures, causing midline shift and potentially herniation.
  • Location:
    • Hypertensive bleeds: Usually in basal ganglia, internal capsule, pons, or cerebellum.
    • Other cause bleeds: More likely to be in the lobes (lobar). This helps in differential diagnosis.
VII. Histopathological Findings (Microscopic Examination):
  • Early Stages: Blood clot surrounded by brain tissue with hypoxia (lack of oxygen) and edema (swelling).
  • Later Stages: Reactive astrocytes (glial cells) proliferate, and the damaged area organizes similarly to an infarct (area of dead tissue from lack of blood supply).
VIII. Prognosis:
  • High Mortality Rate: >40% mortality due to the devastating effects of raised intracranial pressure. This highlights the seriousness of ICH.
Key Concepts to Master:
  • Relationship between hypertension and ICH: This is the cornerstone of understanding this condition.
  • Pathophysiology of haematoma formation and its consequences: Understand the chain of events leading to increased ICP and potential death.
  • Clinical presentation variations based on location: Different areas of the brain will cause different symptoms.
  • Differential diagnosis based on location and etiology: Knowing the likely cause based on the location of the hemorrhage.​
Picture
Published on

Pathology-Sarcoidosis

I. Definition:

  • Sarcoidosis is a multisystem inflammatory disease of unknown etiology characterized by the formation of granulomas (collections of immune cells) in various tissues.

II. Epidemiology:

  • Prevalence: 10-20 cases per 100,000 individuals in the UK.
  • Age of Onset: Peaks between 20-40 years old.
  • Race: Individuals of African descent tend to experience more severe disease.

III. Etiology:

  • Unknown. The underlying cause remains unidentified.

IV. Pathogenesis:

  • The granulomatous inflammation is hypothesized to be a reaction to an unidentified antigen (foreign substance triggering an immune response). The exact antigen remains unknown.

V. Presentation:

  • Multisystemic: Can affect virtually any organ, but most commonly involves lymph nodes, lungs, and skin.
  • Acute Sarcoidosis: Sudden onset with symptoms like:
    • Erythema nodosum (skin inflammation)
    • Anterior uveitis (eye inflammation)
    • Seventh cranial nerve palsy (facial weakness)
    • Bilateral hilar lymphadenopathy (enlarged lymph nodes in the lungs - visible on chest X-ray)
  • Chronic Sarcoidosis: Insidious onset with features such as:
    • Lupus pernio (facial skin lesions)
    • Pulmonary fibrosis (scarring of lung tissue)
    • Posterior uveitis (eye inflammation)

VI. Histopathology (Microscopic Examination):

  • Non-necrotizing granulomas: The hallmark finding is the presence of granulomas that lack central cell death (necrosis).
  • "Naked" granulomas: Sarcoid granulomas are typically well-circumscribed with minimal surrounding inflammatory cells, appearing "naked" under a microscope.
  • Fibrosis: Variable degrees of fibrosis (scarring) may accompany the granulomas.
  • Absence of other causes: Crucially, other explanations for the granulomas (infections, foreign bodies, tumors) must be ruled out.

VII. Prognosis:

  • Acute Sarcoidosis: Generally has a favorable prognosis with spontaneous resolution within 1-2 years after diagnosis.
  • Chronic Sarcoidosis: Carries a higher risk of complications, including progressive pulmonary fibrosis, potentially leading to respiratory failure and right ventricular failure (due to increased pressure in the pulmonary circulation).

Key Differences between Acute and Chronic Sarcoidosis: The table below summarizes the key distinctions:

Feature

Acute Sarcoidosis

Chronic Sarcoidosis

Onset

Sudden

Insidious

Course

Self-limiting (often resolves)

Progressive

Skin Manifestations

Erythema nodosum

Lupus pernio

Eye Involvement

Anterior uveitis

Posterior uveitis

Pulmonary Findings

Bilateral hilar lymphadenopathy

Pulmonary fibrosis

Prognosis

Generally favorable

Potential for serious complications
Published on
Pathology- Vasculitis
Definition: Vasculitis encompasses a group of diseases where inflammation and damage to blood vessels are the primary pathology. This damage can affect vessels of varying sizes, leading to diverse clinical presentations.
Types of Vasculitis:
This guide outlines key features to differentiate between the vasculitides discussed. Remember that overlap exists, and accurate diagnosis often requires biopsy and serological testing (ANCA).
1. Giant Cell (Cranial or Temporal) Arteritis:
  • Vessel Size: Medium and large arteries.
  • Location: Primarily head and neck arteries (temporal artery most commonly).
  • Demographics: Adults >50 years old.
  • Presentation: Weeks to months of fever, anorexia, weight loss, headache, scalp tenderness, jaw claudication (pain with chewing).
  • Serious Complications: Ocular involvement (blindness), aortic aneurysm (25% of cases).
  • Diagnosis: Temporal artery biopsy (positive in only 60% due to focal nature of inflammation); shows lymphohistiocytic infiltrate, media disruption, and often giant cell reaction.
2. Polyarteritis Nodosa:
  • Vessel Size: Medium-sized arteries.
  • Presentation: Systemic vasculitis leading to aneurysm formation and vessel narrowing. Relatively rare with strict diagnostic criteria.
  • Organ Involvement: Gastrointestinal tract (abdominal pain), nervous system (peripheral nerve palsies), muscles (muscle aches).
  • Diagnosis: Imaging showing vessel narrowing and aneurysms; biopsy confirming necrotizing vasculitis.
3. Wegener's Granulomatosis (Granulomatosis with Polyangiitis - GPA):
  • Vessel Size: Small vessels.
  • Presentation: Systemic vasculitis with prominent upper respiratory tract, lung, and kidney involvement. Characterized by c-ANCA positivity.
  • Symptoms: Nasal symptoms, acute renal failure, pulmonary symptoms.
  • Diagnosis:
    • Renal biopsy: Focal segmental necrotizing glomerulonephritis with crescent formation (identical to microscopic polyangiitis).
    • Lung biopsy: Large necrotizing granulomatous inflammation and necrotizing vasculitis.
  • Treatment: Aggressive immunosuppression is crucial to prevent death.
4. Microscopic Polyangiitis (MPA):
  • Vessel Size: Small vessels.
  • Presentation: Systemic vasculitis with significant renal and lung involvement. Characterized by p-ANCA positivity.
  • Demographics: Adults, median age 55.
  • Symptoms: Acute renal failure, pulmonary symptoms.
  • Diagnosis:
    • Renal biopsy: Focal segmental necrotizing glomerulonephritis with crescent formation (identical to Wegener's granulomatosis).
    • Lung biopsy: Marked alveolar hemorrhage and necrotizing capillaritis within alveolar septa.
  • Treatment: Aggressive immunosuppression is essential for survival.
Picture
Published on

Pathology-Systemic Sclerosis (Scleroderma)

I. Definition & Epidemiology:

  • Definition: Systemic sclerosis (SSc) is a rare, multisystem autoimmune disease characterized by excessive fibrous tissue accumulation in various organs. Crucially, this fibrosis leads to organ dysfunction.
  • Epidemiology:
    • Annual incidence: 2-10 per million.
    • Predominantly affects women (30-40 years old).

II. Aetiology & Pathogenesis:

  • Aetiology: The underlying cause of SSc remains unknown.
  • Pathogenesis: An aberrant immune response to an unidentified trigger leads to cytokine production (e.g., IL-4, TGF-β). These cytokines stimulate fibroblasts, resulting in excessive collagen deposition and fibrosis. This fibrosis affects multiple organ systems.

III. Clinical Presentation:

Two main subtypes exist, differing significantly in presentation and prognosis:

  • A. Limited Systemic Sclerosis (lSSc):
    • Onset: Typically begins with Raynaud's phenomenon (cold-induced vasospasm in fingers and toes).
    • Progression: Gradual thickening and tightening of skin (fingers, face, neck).
    • Late Complications (after 10-15 years): Calcium deposits (calcinosis) in finger pads, small bowel involvement, and pulmonary hypertension.
  • B. Diffuse Systemic Sclerosis (dSSc):
    • Onset: More rapid onset with widespread skin thickening, contractures, and ulcers.
    • Visceral Involvement: Early involvement of internal organs including pulmonary fibrosis (lung scarring).
    • Major Complications: Severe hypertension leading to acute renal failure ("scleroderma renal crisis") is a life-threatening complication.

IV. Immunology:

  • Autoantibodies are frequently present, aiding in diagnosis and subtype classification:
    • Anti-nuclear antibodies (ANA): Present in ~65% of patients. Note: ANA is not specific to SSc.
    • Anti-centromere antibodies: Found in 70-80% of lSSc patients. Suggestive of limited disease.
    • Anti-topoisomerase I (Scl-70) antibodies: Present in ~40% of dSSc patients. Associated with diffuse disease and worse prognosis.

V. Prognosis & Treatment:

  • Prognosis: Currently incurable.
  • Treatment: Immunosuppressive therapies are used to manage organ involvement and progressive skin disease.
  • Causes of Death: Primarily due to renal and lung complications (renal failure and pulmonary fibrosis).

VI. Key Differences between lSSc and dSSc:

Feature

Limited Systemic Sclerosis (lSSc)

Diffuse Systemic Sclerosis (dSSc)

Onset

Gradual

Abrupt

Skin Involvement

Limited (fingers, face, neck)

Widespread

Visceral Involvement

Late (e.g., pulmonary hypertension)

Early (e.g., pulmonary fibrosis)

Major Complications

Calcinosis, small bowel issues

Scleroderma renal crisis, pulmonary fibrosis

Associated Antibody

Anti-centromere antibodies

Anti-topoisomerase I (Scl-70) antibodies
Published on
Pathology - Systemic Lupus Erythematosus (SLE)
I. Definition & Epidemiology:
  • Definition: SLE is a multisystem autoimmune disease characterized by the production of autoantibodies targeting nuclear and cytoplasmic antigens. This means the body's immune system mistakenly attacks its own cells.
  • Epidemiology:
    • Incidence: 4 per 100,000 people annually.
    • Predominantly affects women of childbearing age.
    • Higher prevalence in individuals of African and Asian descent.
II. Etiology & Pathogenesis:
  • Etiology (Cause): Unknown. A leading hypothesis suggests defective phagocytosis (the process of engulfing and destroying pathogens) of apoptotic bodies (dying cells). This failure to properly clear apoptotic cells exposes intracellular self-antigens, potentially triggering an autoimmune response.
  • Pathogenesis (Mechanism):
    1. Autoreactive B and T cells (immune cells) become activated.
    2. Immune complexes form: Autoantibodies bind to self-antigens.
    3. These circulating immune complexes deposit in various tissues (skin, joints, kidneys).
    4. Tissue inflammation and damage result from the immune complex deposition. (Visualize this process using Fig 18.1 if available).
III. Clinical Presentation (Symptoms):
SLE's wide-ranging symptoms depend on the affected organs. Remember the diverse nature of its presentations:
  • Common Symptoms: Fatigue, weight loss, low-grade fever.
  • Musculoskeletal: Arthralgia (joint pain).
  • Skin: Scaly red lesions (often on sun-exposed areas).
  • Pulmonary: Pleuritis (lung inflammation), pleural effusion (fluid buildup around lungs), pneumonitis (lung inflammation), potentially leading to pulmonary fibrosis (scarring).
  • Renal: Glomerulonephritis (kidney inflammation), leading to chronic kidney disease. This is a serious complication.
  • Hematological: Anemia (low red blood cell count), lymphopenia (low lymphocyte count), thrombocytopenia (low platelet count).
IV. Immunology (Diagnostic Markers):
Specific autoantibodies are key diagnostic indicators. Note the high prevalence of certain markers:
  • Anti-nuclear antibodies (ANA): >95% of SLE patients test positive. This is a common, but non-specific, finding.
  • Anti-double-stranded DNA (dsDNA) antibodies: 60% of patients. More specific to SLE.
  • Anti-Smith antigen antibodies: 20-30% of patients. Very specific to SLE.
  • Anti-phospholipid antibodies: 20-30% of patients. These antibodies cause a hypercoagulable state (increased risk of blood clots).
V. Prognosis:
  • 15-year survival rate: Approximately 80% from the time of diagnosis.
  • Causes of death: Often related to severe renal (kidney) and pulmonary (lung) complications.
Picture
Published on

Pathology - Dermatitis herpetiformis
Definition: An immunobullous skin disorder marked by severe pruritus, papules, and vesicles, granular IgA deposition in the papillary dermis, and a significant correlation with celiac disease.
Epidemiology • Uncommon. The condition can afflict individuals of any age, while the highest frequency occurs in young people aged 20 to 40 years. Males are impacted twice as frequently as females. This illness is very prevalent in Northern Europe and Ireland. Up to 90% of individuals exhibit indications of celiac disease, although this may be asymptomatic.

Aetiology mediator. • IgA transglutaminase antibodies generated in the gastrointestinal tract seem to be pivotal.

Pathogenesis • IgA transglutaminase antibodies interact with transglutaminase enzymes present in the skin. The fixation of complement induces chemotaxis of neutrophils into the papillary dermis. • Enzymes secreted by neutrophils induce blister development.

Presentation • The rash consists of clusters of papules and vesicles that are highly pruritic. • Preferred locations are the shoulders, back, buttocks, elbows, and knees.

Histopathology Biopsies from first lesions reveal aggregates of neutrophils within the papillary dermis (papillary dermal microabscesses). Biopsies from established lesions reveal a subepidermal blister abundant in neutrophils. Immunofluorescence Direct immunofluorescence of perilesional skin demonstrates granular deposition of IgA in the papillary dermis.

Prognosis: The condition is typically chronic and persistent; nevertheless, it exhibits a significant response to the medication dapsone.



Picture

Kembara Xtra 

Facts about medicine and its subtopic such as anatomy, physiology, biochemistry, pharmacology, medicine, pediatrics, psychiatry, obstetrics and gynecology and surgery.